02171.HK
CARsgen Therapeutics Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 10.95
−2.67%Oct 13, 2026, 00:15 UTC
CARsgen Therapeutics Holdings Ltd. announced that the first patient in China had been infused in the Phase I registration clinical trial of CT0596 for relapsed or refractory multiple myeloma.
Sep 29, 2026, 00:07 UTC
CARsgen Therapeutics announced that the first patient has been dosed in a China Phase I registrational clinical trial of its CD19/CD20-targeted universal CAR-T product CT1190B for relapsed/refractory large B-cell lymphoma.
Source:Aug 19, 2026, 08:12 UTC
CARsgen Therapeutics announced at its results meeting on August 19, 2026, that Kailimei has been prescribed at Beijing Gaobo Hospital, with cell collection completed at Fudan University-affiliated Zhongshan Hospital and at Jiahui International Cancer Center for a foreign patient.
Source:Aug 18, 2026, 15:16 UTC
CARsgen Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB 61.92 million, up 21.5% year-on-year, and a narrowed net loss of RMB 66.66 million, compared with a loss of RMB 75.34 million in the same period last year.
Source:Aug 7, 2026, 00:13 UTC
Carsgen Therapeutics announced that its universal CAR-T therapy CT1190B received clinical trial approval from China's National Medical Products Administration for the treatment of relapsed/refractory large B-cell lymphoma.
Source:Aug 4, 2026, 00:15 UTC
Carsgen Biotherapeutics announced that CT0596, a universal CAR-T cell product targeting BCMA, has received approval from China's National Medical Products Administration for a new drug clinical trial application, for the treatment of relapsed/refractory multiple myeloma.
Source: